GlobeNewswire: Standard BioTools Inc. Contains the last 10 of 276 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T20:27:55ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/18/2847767/0/en/Standard-BioTools-Announces-Exchange-of-All-Outstanding-Series-B-Convertible-Preferred-Stock-for-Common-Stock.html?f=22&fvtc=4&fvtv=28046Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock2024-03-18T12:12:23Z<![CDATA[SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it has exchanged all outstanding shares of its Series B Convertible Preferred Stock (the “Series B Preferred”) for shares of common stock pursuant to an agreement with stockholders affiliated with Viking Global Investors (“Viking”) and Casdin Capital (“Casdin").]]>https://www.globenewswire.com/news-release/2024/02/28/2837395/0/en/Standard-BioTools-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html?f=22&fvtc=4&fvtv=28046Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results2024-02-28T21:01:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced financial results for the fourth quarter and fiscal year ended December 31, 2023.]]>https://www.globenewswire.com/news-release/2024/02/26/2835096/0/en/Standard-BioTools-and-Next-Gen-Diagnostics-Announce-Partnership-to-Provide-Complete-Automation-of-Low-Cost-Pathogen-Sequencing.html?f=22&fvtc=4&fvtv=28046Standard BioTools and Next Gen Diagnostics Announce Partnership to Provide Complete Automation of Low-Cost Pathogen Sequencing2024-02-26T13:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – and Next Gen Diagnostics announce the execution of a long-term agreement aimed at revolutionizing the automation of sample preparation for pathogen whole genome sequencing. Under the exclusive agreement, Standard BioTools™ will manufacture the NGD-100, a version of its microfluidics-based Biomark™ X9 System customized for NGD and optimized for automated pathogen WGS library preparation.]]>https://www.globenewswire.com/news-release/2024/02/22/2834067/0/en/Standard-BioTools-to-Participate-in-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=28046Standard BioTools to Participate in Upcoming Investor Conferences2024-02-22T21:05:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that management will participate in the following investor conferences:]]>https://www.globenewswire.com/news-release/2024/02/14/2829084/0/en/Standard-BioTools-Announces-Conference-Call-and-Webcast-for-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-February-28-2024.html?f=22&fvtc=4&fvtv=28046Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2023 Financial Results on February 28, 20242024-02-14T13:30:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that it will report fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, after the close of the market.]]>https://www.globenewswire.com/news-release/2024/02/07/2825209/0/en/Standard-BioTools-and-Navignostics-Announce-Collaboration-Agreement-to-Advance-Imaging-Capabilities-in-Personalized-Medicine.html?f=22&fvtc=4&fvtv=28046Standard BioTools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine2024-02-07T13:30:35Z<![CDATA[Increasing access to Imaging Mass Cytometry in pharmaceutical and clinical research settings Increasing access to Imaging Mass Cytometry in pharmaceutical and clinical research settings]]>https://www.globenewswire.com/news-release/2024/01/08/2805468/0/en/Standard-BioTools-Announces-Preliminary-Fourth-Quarter-and-Full-Year-2023-Revenue.html?f=22&fvtc=4&fvtv=28046Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 Revenue2024-01-08T13:30:32Z<![CDATA[Achieving scale with pro forma full year 2023 revenue of approximately $192 million Achieving scale with pro forma full year 2023 revenue of approximately $192 million]]>https://www.globenewswire.com/news-release/2024/01/05/2804664/0/en/Standard-BioTools-Completes-Merger-with-SomaLogic-Creating-a-Diversified-and-Scaled-Leader-in-Life-Sciences-Tools.html?f=22&fvtc=4&fvtv=28046Standard BioTools Completes Merger with SomaLogic, Creating a Diversified and Scaled Leader in Life Sciences Tools2024-01-05T13:46:55Z<![CDATA[Establishes Leading Platform of Complementary Multi-omic Technologies with Enhanced Scale and Commercial Reach; Strengthened Balance Sheet to Self-Fund Future Growth Initiatives Establishes Leading Platform of Complementary Multi-omic Technologies with Enhanced Scale and Commercial Reach; Strengthened Balance Sheet to Self-Fund Future Growth Initiatives]]>https://www.globenewswire.com/news-release/2024/01/05/2804437/0/en/Standard-BioTools-Stockholders-Approve-Merger-with-SomaLogic.html?f=22&fvtc=4&fvtv=28046Standard BioTools Stockholders Approve Merger with SomaLogic2024-01-05T03:23:06Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health, today announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with SomaLogic (Nasdaq: SLGC) at its Special Meeting of Stockholders.]]>https://www.globenewswire.com/news-release/2023/12/29/2802184/0/en/Glass-Lewis-Recommends-Standard-BioTools-Stockholders-Vote-FOR-All-Proposals-Relating-to-Proposed-Merger-with-SomaLogic.html?f=22&fvtc=4&fvtv=28046Glass Lewis Recommends Standard BioTools Stockholders Vote “FOR” All Proposals Relating to Proposed Merger with SomaLogic2023-12-29T22:04:12Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Dec. 29, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health, today announced that a second leading independent proxy advisory firm, Glass, Lewis & Co. (“Glass Lewis”), has recommended that all Standard BioTools stockholders vote “FOR” all proposals relating to the pending merger with SomaLogic at the Company’s upcoming Special Meeting of Stockholders to be held on January 4, 2024.]]>